Trial · NCT00724009

Clofarabine Bone Marrow Cytoreduction

NCT00724009, Phase 2, Completed, University of Chicago; results first posted 2014-03-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Clofarabine Bone Marrow Cytoreduction. Trials, record NCT00724009. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00724009

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Clofarabine Bone Marrow Cytoreduction
NCT number: NCT00724009
Status: Completed
Phases: Phase 2
Enrollment: 29 participants, actual
Lead sponsor: University of Chicago
Conditions: Leukemia
Interventions: Clofarabine
First posted: 2008-07-29
Last updated: 2014-03-18
Results first posted: 2014-03-18

Source ClinicalTrials.gov

Registered outcomes8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Cytoreductive Response	Day 12	Percent of patients achieving cytoreductive response of marrow cellularity \<20% and blasts \< 10%
Secondary	Number of Participants With Renal Adverse Events	Day 12	Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Secondary	Number of Participants With Hepatic (Total Bilirubin) Adverse Events	Day 12	Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Secondary	Number of Participants With Hepatic (SGOT) Adverse Events	Day 12	Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Secondary	Number of Participants With Cardiac Adverse Events	Day 12	Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Secondary	Number of Participants With Skin Adverse Events	Day 12	Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Secondary	Number of Participants Infection Adverse Events	Day 12	Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Secondary	Leukemia Free Survival	2 years	Time to event analysis used the day of transplant as day 0.

Source ClinicalTrials.gov

Outcomes8

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Cytoreductive Response	Day 12		percentage of participants	NUMBER
SECONDARY	Number of Participants With Renal Adverse Events	Day 12		participants	NUMBER
SECONDARY	Number of Participants With Hepatic (Total Bilirubin) Adverse Events	Day 12		participants	NUMBER
SECONDARY	Number of Participants With Hepatic (SGOT) Adverse Events	Day 12		participants	NUMBER
SECONDARY	Number of Participants With Cardiac Adverse Events	Day 12		participants	NUMBER
SECONDARY	Number of Participants With Skin Adverse Events	Day 12		participants	NUMBER
SECONDARY	Number of Participants Infection Adverse Events	Day 12		participants	NUMBER
SECONDARY	Leukemia Free Survival	2 years	One patient with refractory AML underwent conditioning but died 1 day before stem cell infusion due to sepsis (grade 5 infection)	days	MEDIAN

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Cytoreductive Response	Clofarabine		52	percentage of participants
Number of Participants With Renal Adverse Events	Clofarabine	Grade 1-2	9	participants
Number of Participants With Renal Adverse Events	Clofarabine	Grade 3-4	1	participants
Number of Participants With Hepatic (Total Bilirubin) Adverse Events	Clofarabine	Grade 1-2	14	participants
Number of Participants With Hepatic (Total Bilirubin) Adverse Events	Clofarabine	Grade 3-4	3	participants
Number of Participants With Hepatic (SGOT) Adverse Events	Clofarabine	Grade 1-2	14	participants
Number of Participants With Hepatic (SGOT) Adverse Events	Clofarabine	Grade 3-4	9	participants
Number of Participants With Cardiac Adverse Events	Clofarabine	Grade 1-2	2	participants
Number of Participants With Cardiac Adverse Events	Clofarabine	Grade 3-4	0	participants
Number of Participants With Skin Adverse Events	Clofarabine	Grade 1-2	1	participants

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Clofarabine	29
Overall Study	COMPLETED	Clofarabine	29
Overall Study	NOT COMPLETED	Clofarabine	0

Source ClinicalTrials.gov

Adverse events9

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Renal (creatinine)	Renal and urinary disorders	Clofarabine	9	29	9
other	Hepatic (total bilirubin)	Hepatobiliary disorders	Clofarabine	14	29	14
other	Hepatic (SGOT)	Hepatobiliary disorders	Clofarabine	14	29	14
other	Cardiac	Cardiac disorders	Clofarabine	2	29	2
other	Skin	Skin and subcutaneous tissue disorders	Clofarabine	1	29	1
serious	Renal (creatine)	Renal and urinary disorders	Clofarabine	1	29	1
serious	Hepatic (total bilirubin)	Hepatobiliary disorders	Clofarabine	3	29	3
serious	Hepatic (SGOT)	Hepatobiliary disorders	Clofarabine	9	29	9
serious	Infection	Infections and infestations	Clofarabine	12	29	12

Source ClinicalTrials.gov

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Clofarabine
Total, other adverse events	Clofarabine	26	29
Total, serious adverse events	Clofarabine	22	29

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00724009

GET https://conductscience.org/api/trials/v1/NCT00724009/registered

API reference For AI assistants